| Document |
Document Title |
|
WO/2024/089421A1 |
The invention relates to compounds of formula (I) and related aspects.
|
|
WO/2024/079682A1 |
The present invention relates to a sulfoximine compound having a novel structure, stereoisomers thereof or pharmaceutically acceptable salts thereof, and a use thereof for preventing or treating histone deacetylase-mediated diseases The ...
|
|
WO/2024/081885A1 |
Oxadiazole antibiotics that exhibit bactericidal activity against C. difficile vegetative cells. We screened a library of 75 oxadiazoles against C. difficile ATCC 43255. The findings from this collection served as the basis for the synth...
|
|
WO/2024/079128A1 |
The invention relates to compounds and their therapeutic use, said compounds having the formula (I): wherein, for example, Z is representing a (II) X is representing a NR5R6 group wherein R5 and R6 are hydrogen, R1 is represe...
|
|
WO/2024/074126A1 |
Provided are a 4-methylsulfonylbenzamide compound having a structure represented by general formula (I) and having a sulfur-containing substituent at position 3, a stereoisomer thereof, an agriculturally acceptable salt thereof, a prepar...
|
|
WO/2024/067560A1 |
Disclosed in the present invention are a sulfonamide compound and the medical use thereof as a STING inhibitor, specifically, a compound as represented by formula (I) or a pharmaceutically acceptable salt or ester or solvate thereof, whi...
|
|
WO/2024/070757A1 |
The present invention addresses the problem of providing a compound that, when being mixed with a liquid crystal compound to align the liquid crystal compound, suppresses disarray in the alignment of the liquid crystal compound. A compou...
|
|
WO/2024/068519A1 |
The present invention relates to 3-heteroaryl-5-chlorodifluoromethyl-1,2,4-oxadiazole compounds as well as the uses thereof for controlling harmful microorganisms, in particular phytopathogenic fungi, in crop protection.
|
|
WO/2024/068517A1 |
The present invention relates to 3-heteroaryl-5-chlorodifluoromethyl-1,2,4-oxadiazole compounds as well as the uses thereof for controlling harmful microorganisms, in particular phytopathogenic fungi, in crop protection.
|
|
WO/2024/053316A1 |
The present invention addresses the problem of providing a novel compound, which binds to extracellular vesicles and enables size measurement by liquid chromatography, etc., an extracellular vesicle staining agent and a fluorescent stain...
|
|
WO/2024/042146A2 |
The present invention provides covalent fluorescent probes for cannabinoid receptor 2 ("CB2") having the general formula (I) wherein X, n, p, and R1 to R4 are as described herein, compositions including the compounds, processes of manufa...
|
|
WO/2024/040190A1 |
Provided are compounds of Formula (I). Also provided is a pharmaceutically acceptable composition comprising a compound of Formula (I), or a pharmaceutically acceptable salt thereof. Also provided are methods of using a compound of Formu...
|
|
WO/2024/032501A1 |
Provided are a compound of formula 0, a stereoisomer thereof, a tautomer thereof, a geometric isomer thereof, an enantiomer thereof, a diastereomer thereof, a racemate thereof, a polymorph thereof, a solvate thereof, a hydrate thereof, a...
|
|
WO/2024/030121A1 |
The present application discloses novel compounds, and compositions comprising said compounds, that are effective small-molecule agonists that stimulate overproduction of cytosolic cyclic AMP (cAMP) in Mycobacterium tuberculosis (Mtb) wh...
|
|
WO/2024/026359A1 |
In accordance with the purpose(s) of the present disclosure, as embodied and broadly described herein, the disclosure, in one aspect, relates to compounds that are inhibitors for thioredoxin glutathione reductase (TGR), which is key for ...
|
|
WO/2024/018016A1 |
The invention relates to crystalline forms of compounds of formula (I-A) and (I-B) (I-A) (I-B) compositions comprising said crystalline forms and methods of their use as fungicides.
|
|
WO/2024/020350A1 |
The present disclosure provides, in part, compounds of formula (I): wherein the variables are as defined herein, pharmaceutical compositions comprising the compounds, and methods of using the compounds to treat physiological disorders, s...
|
|
WO/2024/019685A2 |
Within the scope of the invention, 18 novel 3,5-disubstituted-1,2,4-oxadiazole derivative compounds were synthesized. The synthesized compounds were found to have high inhibitory activity on carbonic anhydrase enzymes I and II (CA I and ...
|
|
WO/2024/006055A1 |
Antibiotic resistance, by definition, occurs when a bacterial pathogen is no longer effectively treated with a particular drug when formerly it was. With the rise in resistance and public awareness of "superbugs," there is a need for new...
|
|
WO/2023/250107A1 |
The present disclosure relates generally to methods for the preparation of Compound (I-1): I-1 or a stereoisomer or mixture of stereoisomers thereof, or salt of each thereof, as well as compounds and salts which are useful in the synthes...
|
|
WO/2023/239839A1 |
Disclosed herein are compounds having an isoxazole core or an oxadiazole core or a pharmaceutically acceptable salt thereof and compositions useful for preventing and/or treating a neurological disorder, a disorder associated with excess...
|
|
WO/2023/227734A1 |
The invention relates to compounds that are inhibitors of Flavivirus NS2B-NS3 proteases and inhibit replication of flavivirus in cells. Compounds of this invention are useful alone or in combination with other agents for use in the treat...
|
|
WO/2023/223174A1 |
The present disclosure relates to a pharmaceutical composition for preventing or treating idiopathic pulmonary fibrosis, comprising a compound represented by formula I, optical isomers thereof or pharmaceutically acceptable salts thereof...
|
|
WO/2023/225327A1 |
Compounds, compositions, and methods for making and using the compounds for treatment of cancer are provided herein. Mechanistically, these compounds were found to bind to RPS23 and were effective in activating the inducible stress respo...
|
|
WO/2023/223257A1 |
The specification relates to 2-(difluoromethoxy)-5-(5-((5-fluoroadamantan-2-yl)(methyl)am
ino)- 1,3,4-oxadiazol-2-yl)phenol or 5-(3-(((1-cyclohexyl-1H-tetrazol-5-yl)methyl)(methyl)amino)-
1,2,4- oxadiazol-5-yl)-2-fluorophenol, and to pha...
|
|
WO/2023/224371A1 |
The present invention relates to a composition for preventing or treating neuroinflammatory diseases comprising a novel oxadiazole derivative compound or a pharmaceutically acceptable salt thereof. The present invention has excellent act...
|
|
WO/2023/218203A1 |
The present invention relates to compounds that are MALT1 inhibitors. The compounds have the structural formula I defined herein. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical c...
|
|
WO/2023/215775A1 |
A compound of Formula (I) or a pharmaceutically acceptable salt thereof, is described, wherein the substituents are as defined herein. Pharmaceutical compositions comprising the same arid method of using the same for treatment of medical...
|
|
WO/2023/209191A1 |
The invention concerns a novel class of Prolyl oligopeptidase binding ligands, a pharmaceutical composition comprising same, the use of said ligands as medicaments, particularly, but not exclusively to promote autophagy and/or treat a di...
|
|
WO/2023/196538A1 |
Substituted benzofuran, benzothiophene, and indole carboxamide compounds, conjugates, and pharmaceutical compositions for use as immunotherapeutics in the treatment of cancer, such as solid tumors, are disclosed herein. The disclosed com...
|
|
WO/2023/195809A1 |
The present invention relates to a novel compound having histone deacetylase 6 (HDAC6) inhibitory activity, a method for preparing the same, and uses thereof. The novel compound according to the present invention, a stereoisomer thereof ...
|
|
WO/2023/164057A1 |
The disclosure herein provides compounds and pharmaceutical compositions of Formula (I) for the modulation of IL-17A. Compounds and pharmaceutical compositions of Formula (I) are useful for the treatment of inflammatory conditions, such ...
|
|
WO/2023/158795A1 |
Provided are compounds of the Formula (I): or pharmaceutically acceptable salts thereof, which are useful for the inhibition of DHX9 and in the treatment of a variety of DHX9 mediated conditions or diseases, such as cancer.
|
|
WO/2023/152767A1 |
The present invention provides crystalline polymorphic Form M1, M2, M3, M4, M5 and M6 of Ozanimod hydrochloride. It also provides process for the preparation of the same.
|
|
WO/2023/145804A1 |
The purpose of the present invention is to provide a novel B0AT1 inhibitor. The present invention relates to a compound represented by formula (I): (the symbols in the formula are as described in the description) or a salt thereof. The p...
|
|
WO/2023/140228A1 |
As a means that can be applied to a protein-mixed system and can detect a modified or aggregated protein with high sensitivity, a method for visualizing the modified state or the aggregated state of a protein is provided, the method bein...
|
|
WO/2023/131349A1 |
A treprostinil coupled nitric oxide (NO) donor drug as shown in formula I below, a pharmaceutical composition thereof and a use thereof.
|
|
WO/2023/116877A1 |
Disclosed is a heterocyclic compound as a TEAD inhibitor. The heterocyclic compound has the structure represented by formula (I): the definition of each group in formula (I) is as described herein. The heterocyclic compound can be used f...
|
|
WO/2023/122276A1 |
Provided herein are small molecule active metabotropic glutamate subtype-2 and -3 receptor positive allosteric modulators (PAMS), compositions comprising the compounds, and methods of using the compounds and compositions comprising the c...
|
|
WO/2023/092175A1 |
The invention relates generally to a compound of Formula (I), wherein R1 is a bicyclic fused heterocyclic moiety and R2 is H or F. The compound of Formula (I) or a pharmaceutically acceptable salt thereof has potential medical use in the...
|
|
WO/2023/080765A1 |
The present invention pertains to an oxadiazole derivative and a composition containing same for preventing or treating NADPH oxidase (NOX)-related diseases. The present invention can be used to treat NADPH oxidase (NOX)-related diseases...
|
|
WO/2023/070700A1 |
Provided are a compound using fluorene as a core, and a preparation method therefor and the use thereof. By means of changing the types of a donor and an acceptor and bonding positions, an electroluminescent device having a series of blu...
|
|
WO/2023/072671A1 |
The present invention relates to the use of strobilurin type compounds of formula I and the N- oxides and the salts thereof for combating phytopathogenic fungi containing an amino acid substitution F129L in the mitochondrial cytochrome b...
|
|
WO/2023/073115A1 |
The present invention relates to the use of the compound of the formula (I) and the composition thereof as control agent for plant diseases caused by fungi, oomycetes and bacteria. Plant pathogens produce self-aggregating proteins, like ...
|
|
WO/2023/069721A2 |
Provided herein are USP28 inhibitors, pharmaceutical compositions, methods of their preparation, and methods of their use in treatment and/or diagnosis.
|
|
WO/2023/064771A1 |
HDAC-7 inhibitors and uses thereof are provided, including their uses as therapeutic agents for treating brain cancer and/or solid tumors, for example, glioblastoma multiforme (GBM). In some embodiments, provided herein are HDAC-7 inhibi...
|
|
WO/2023/062627A1 |
Provided herein are compounds that inhibit the protein-protein interaction of serine acetyltransferase (SAT) with O-acetyl serine sulfhydrylase (OASS), and can therefore be used as herbicides.
|
|
WO/2023/061095A1 |
The present invention relates to the field of medicinal chemistry. Disclosed in the present invention are a 14-chloro-β-elemene nitric oxide donor type derivative, preparation and application thereof in preparing an antitumor drug. The ...
|
|
WO/2023/043938A1 |
Provided herein are compounds and methods for the treatment of cancer. The methods include administering to a subject in need a therapeutically effective amount of a sulfamide RNR inhibitor disclosed herein.
|
|
WO/2023/043803A1 |
Disclosed herein are FABP4 and FABP5 inhibitor compounds and their use in pharmaceutical compositions for treating diseases relating to fatty acid metabolism, including cancer. Also disclosed herein are methods for preparing the disclose...
|
